Vol. 6 No. 9 (2026): September
Reimbursement Reviews

Ritlecitinib (Litfulo)

decorative image of the issue cover

Published September 17, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ritlecitinib (Litfulo), 50 mg, capsules, oral use.
  • Indication: For the treatment of adults and adolescents 12 years and older with severe alopecia areata.